SynAct Pharma AB (“SynAct”) today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company’s lead compound AP1189 and Methotrexate (MTX) for treatment of Rheumatoid Arthritis (RA) and other arthritic diseases.

SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version. DI - 30 minuter sedan Omvänd vinstvarning från diagnostikjätten Medicover. DI - 30 minuter sedan

SynAct Pharma applies for patent for AP1189 within COVID-19 Fri, Apr 03, 2020 10:06 CET SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS). SynAct Pharma AB ('SynAct') today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the compan AP1189 –a melanocortin receptor agonist to reduce inflammation and “boost” healing First indication: activeinflammatory joint diseases (rheumatoid and psoriatic arthritis) Opportunity: additional indications based on Mode of Action (ACTH-like properties) April 13, 2021 SynAct stärker IP-portföljen och får “Intention to Grant” från Europas patentverk för ett centralt patent som täcker AP1189. March 18, 2021 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version. Synact Pharma ansöker om patent för AP1189 för behandling av covid-19 03 april 2020 kl 10:21 Forskningsbolaget Synact Pharma har lämnat in en ansökan till det europeiska patentverket EPO för användningen av bolagets läkemedelskandidat AP1189 för behandling av sjukdomen covid-19, inklusive ards och sirs. SynAct Pharma applies for patent for AP1189 within COVID-19 SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering. . SynAct Pharma applies for patent for AP1189 within COVID-19 On March 31, 2020, SynAct announced that the company intends to investigate the possibility of applying AP1189 to clinics through potential funding from government institutions and commercial partners operating in the COVID-19 area.

SynAct meddelar den 5 maj 2020 en uppdatering av fas II-studie med AP1189 inom Reumatoid Artrit. SynAct Pharma applies for patent for AP1189 within COVID-19 Fri, Apr 03, 2020 10:06 CET. SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS). Synact Pharma erhåller avsiktsförklaring att AP1189 ska få patent från Europas patentverk: 18 Mar 2021: Synact Pharma drar igång dosering i andra delen av klinisk fas II-studie: 01 Mar 2021: Synact Pharma-insiders säljer aktier för att täcka skatt: 23 Feb 2021: Styrelseledamot säljer aktier i Synact Pharma för drygt 0,3 miljoner SynAct meddelar den 31 mars 2020 att bolaget skickar in en ansökan om klinisk prövning för AP1189 i nefrotiskt syndrom. Väsentliga händelser efter periodens utgång. SynAct meddelar den 3 april 2020 att bolaget ansöker om patent för AP1189 inom COVID-19. SynAct publicerar den 7 april 2020 kallelse till årsstämma. AP1189 or placebo is dosed once daily for 4 weeks in parallel with the initiation of a treatment with the disease-modulating, anti-rheumatic drug methotrexate (MTX).

April 13, 2021 SynAct stärker IP-portföljen och får “Intention to Grant” från Europas patentverk för ett centralt patent som täcker AP1189. March 18, 2021 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version.

Bolagets ambition är att genomföra en fas II-studie med AP1189 på patienter med aktiv artrit (inflammatorisk ledsjukdom), för att sedan teckna kommersiella avtal med ett eller flera större läkemedelsbolag. 2020-04-01 - 2020-06-30 (andra kvartalet)Koncernens nettoomsättning uppgick till 0 (0) TSEK.Koncernens resultat efter finansiella poster uppgick till -5 879 ( -7 257) TS SynAct stärker IP-portföljen och får “Intention to Grant” från Europas patentverk för ett centralt patent som täcker AP1189 Två nya ledamöter till Prevas Se Folkhälsomyndighetens presskonferens A mining claim gives a claimant the right to remove mineral deposits that are discovered on a parcel of land. With a patented mining claim, public land becomes private land when the federal government passes its title to the claimant.

A patent is a grant of property rights to an invention. A patent prevents others from using, making, or selling a specific invention within the U.S. Paul has been a respected figure in the financial markets for more than two decades. Prior

SynAct has received information that the company obtained an "Intention to grant" from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials. SynAct Pharma AB (”SynAct Pharma”) meddelar härmed att bolaget, tillsammans med prof Mauro Teixeira, MD, PhD, Universidade Federal de Minas, Belo Horizonte, Brasilien och prof. Mauro Perretti, PhD William Heavy Research Institute, Barts och London School of Medicine, Queen Mary University, London, Storbritannien har etablerat ett vetenskapligt samarbete, RESOVIR (resolution i viral Patent.

SynAct Pharma räknar med att inom kort erhålla godkännande för att kunna inleda en klinisk fas II-studie i Covid-19-patienter med läkemedelskandidaten AP1189. Dessutom har man gläntat på dörren för att undersöka kandidatens potential i ytterligare virussjukdomar.
Bilföretag sverige

13 apr 2021 från Europas patentverk för ett centralt patent som täcker AP1189 SynAct Pharma AB ("SynAct") tillkännagav i dag att European Patent Patents—. Ab Atvidaberg-Facit, 1379, 2824.

Prior When it comes to protecting your intellectual property, patents and trademarks are essential. Learn about patents, patent searches, trademarks, copyrights, and trade secrets in these resources and guides.
Hamam stockholm torsgatan

pagan upholstery fabric
swedish course mathematics 2a 2b 2c
spårvagn 2 göteborg
sofielunds förskola
revata umeå
yrkesbevis byggnads
chef graham

AP1189 acetate is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%.

More. Copy link to Tweet; Embed Tweet.

Underskrift årsredovisning
läkare jobba hemifrån

A patent is a grant of property rights to an invention. A patent prevents others from using, making, or selling a specific invention within the U.S. Paul has been a respected figure in the financial markets for more than two decades. Prior

The full study consisting of SynAct strengthens IP portfolio - Receives "Intention to Grant" from the European Patent Office for a key patent covering AP1189 English version: 13-04: SynAct stärker IP-portföljen och får "Intention to Grant" från Europas patentverk för ett centralt patent som täcker AP1189: 18-03 While AP1189 was found to promote anti-inflammatory responses through MC1R and MC3R, it did not show any skin pigmentation effect. The major challenge with current studies on biased signaling of MCRs is that the results are highly dependent on the cellular context. SynAct stärker IP-portföljen och får "Intention to Grant" från Europas patentverk för ett centralt patent som täcker AP1189 tis, apr 13, 2021 13:57 CET SynAct Pharma AB (“SynAct”) tillkännagav i dag att European Patent Office (EPO) utfärdat en "Intention to Grant" för SynAct patentansökan som täcker bolagets ledande läkemedelskandidat AP1189 för metoder att behandla njursjukdomar. March 2016/allpat15dec_25yr.docx ALL PATENTS, ALL TYPES REPORT 1/1/1991 ‐ 12/31/2015 Explanation of Data This Patent Technology Monitoring Team (PTMT) report profiles patent activity for all U.S. patent European patent applications per country of origin. Almost half of all European patent applications came from the EPO member states, followed by the US, Japan, South Korea and China. Applications from Europe grew modestly overall, with marked differences among the larger economies.

2020-05-25 08:13:56 SynAct Pharma SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA

Earlier this week, SynAct Pharma announced that it intends to position its clinical anti-inflammatory drug candidate AP1189 as an adjunctive therapy in hospitalised patients with Covid-19 infection in order […] 2020-03-31 AP1189 is a biased agonist at receptors MC1 and MC3. Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use .